Abstract:Objective The renin-angiotensin system (RAS) is implicated in the development of hypertensive glomerulosclerosis, However, no experimental evidence exists that clearly demonstrates activation of glomerular RAS in hypertensive nephropathy, We used stroke-prone spontaneously hypertensive rats (SHRSP) to examine whether RAS components are increased in glomeruli of SHRSP and whether this increase leads to an increase in mRNA levels for transforming growth factor-beta 1 (TGF-beta 1), Methods We examined the sequential changes of urinary albumin excretion (UAE), morphology, and glomerular mRNA expression for TGF-beta 1 and fibronectin (FN) in relation to glomerular mRNA expression for angiotensinogen (ATN), angiotensin converting enzyme (ACE), angiotensin II type 1a (AT1a), and type 1b (AT1b) receptors, and intervention with angiotensin II type 1. receptor antagonist candesartan and equihypotensive hydralazine, Results In SHRSP, UAE was normal at 9 weeks of age, but became higher, beginning at 12 weeks of age, than that in the age-matched Wistar-Kyoto (WKY) rats, while SH RSP showed no glomerulosclerosis until 14 weeks of age; it was marked at 24 weeks. Plasma renin activity and plasma angiotensin II level was equivalent in the 9- and 12-week-old SHRSP and the WKY rats; both parameters, however, were elevated in 24-week-old SHRSP as compared with age-matched control. RNase protection assays showed that glomerular levels of ATN, ACE, and AT1a and AT1b receptors mRNA were significantly increased in 9-, 12-, and 14-week-old, but not in 24-week-old SHRSP, compared with age-matched WKY rats. Northern blot analysis showed that glomerular levels of TGF-beta 1 and FN mRNA were higher in SHRSP than in WKY rats at all time points. Candesartan reduced UAE to control levels, whereas hydralazine reduced UAE but not to control levels. Candesartan administration for 12 weeks virtually prevented the progression of glomerulosclerosis. While candesartan reduced mRNA levels for RAS components, TGF-beta 1 and FN to control levels, hydralazine was not effective in this respect. Conclusion Results suggest that increases in glomerular RAS components that occur independently of circulating RAS alter glomerular permselectivity and increase the glomerular expression of TGF-PI and FN in young SHRSP. Findings in old SHRSP suggest that altered glomerular permselectivity and an increased glomerular expression of TGF-beta 1 and FN may be associated with the activation of systemic RAS, JHypertens 2000, 18:1247-1255 (C) Lippincott Williams & Wilkins.

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading

Aliskiren Ameliorates Pressure Overload-Induced Heart Hypertrophy and Fibrosis in Mice

Inhibition of Renin Activity by Aliskiren Ameliorates Diabetic Nephropathy in Type 1 Diabetes Mouse Model

Aliskiren protects against myocardial ischaemia-reperfusion injury via an endothelial nitric oxide synthase dependent manner

Direct Renin Inhibition with Aliskiren Protects Against Myocardial Ischemia/Reperfusion Injury by Activating Nitric Oxide Synthase Signaling in Spontaneously Hypertensive Rats

Direct Inhibition with Aliskiren Normalizes Blood Pressure in Cyp1a1‐Ren2 Transgenic Rats with Inducible ANG II‐Dependent Malignant Hypertension

Protective Effects of Aliskiren and Valsartan in Mice with Diabetic Nephropathy.

GW24-e3848 The organ protective effect of direct renin inhibitor in a mouse model of type 2 diabetes

Aliskiren Enhances Protective Effects of Valsartan Against Type 2 Diabetic Nephropathy in Mice

Advances of renin inhibitor aliskiren in the treatment of hypertension

Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase-Deficient Mice.

Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.

Renalase Protects Against Salt-Induced Kidney Injury And Inflammation By Inhibiting The Activation Of The Akt-1 Signaling Pathways

Renal Denervation Attenuates Aldosterone Expression and Associated Cardiovascular Pathophysiology in Angiotensin II-induced Hypertension.

Inhibition of renin activity slows down the progression of HIV-associated nephropathy.

Candesartan Prevents the Progression of Glomerulosclerosis in Genetic Hypertensive Rats.

Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice with Chronic Cerebral Hypoperfusion

Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

Antiproteinuric and Hyperkalemic Mechanisms Activated by Dual Versus Single Blockade of the RAS in Renovascular Hypertensive Rats

The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity

Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.